Gelesis is a biotherapeutics company advancing a novel hydrogel platform technology to treat obesity, help with weight management, and other chronic metabolic diseases.
GLS
0.18 as of 3/27/23
| Date | Funding Round | Funding Raised | Price per Share | IPO Valuation |
|---|---|---|---|---|
| 7/19/2020 | Series Growth 3 | $801MM | $XXX.XX | $XXX.XX |
| 2/28/2018 | Series Growth 2 | $215.68MM | $XXX.XX | $XXX.XX |
| 12/30/2015 | Series Growth | $181.84MM | $XXX.XX | $XXX.XX |
| 3/26/2015 | Series A-5 | $147.36MM | $XXX.XX | $XXX.XX |
| 5/16/2014 | Series A-4 | $33.3MM | $XXX.XX | $XXX.XX |
| 1/3/2008 | Series A-1, A-2, and A-3 | $21.45MM | $XXX.XX | $XXX.XX |
